SAN FRANCISCO, Dec. 9, 2019 /PRNewswire/ -- The global point-of-care glucose testing market recorded a revenue of USD 6,017.83 million in 2018 and is expected to reach USD 7,308.69 million by 2025 growing at a CAGR of 2.82%, according to a new report by Grand View Research, Inc. An increase in the demand for point-of-care testing (POCT) has been witnessed in recent years. As compared to the conventional laboratory testing performed central lab settings, glucose POCT aids in performing effective diagnosis at the patient's bedside. Easy and convenient operation of POCT has largely favored the growing usage of glucose meters across medical settings.

Key suggestions from the report:

• Accu-Chek Inform II accounted for the largest revenue share in 2018 and is anticipated to maintain this trend throughout the forecast period
• Bayer CONTOUR blood glucose monitoring system is set to grow with a CAGR of 5.5% from 2019-2025
• In terms of volume, the i-STAT ranked above all owing to its multipurpose utility in the diagnostics industry
• North America is the leading regional market due to the higher penetration of novel diagnostic techniques
• Asia Pacific has registered the fastest growth rate owing to numerous untapped growth opportunities in diagnostics and ever-increasing prevalence of diabetes
• A robust network of local manufacturers has significantly contributed to the revenue generated in this region Some of the key market participants are F. Hoffmann-La Roche Ltd., Abbott, LifeScan, Inc., and Nova Biomedical among others

Read 145 page research report with ToC on "Point-of-Care Glucose Testing Market Size, Share & Trends Analysis Report By Product (Accu Check Aviva Meter, Onetouch Verio Flex, i-STAT, Freestyle Lite, True Metrix), And Segment Forecasts, 2019 - 2025'' at: https://www.grandviewresearch.com/industry-analysis/point-of-care-glucose-testing-market

The demand for performing bedside monitoring of blood sugar levels efficiently in a capillary blood sample and the need to ensure better management of carbohydrate metabolism has propelled the point-of-care glucose testing market players to launch innovative glucose meters in the market. Various companies are investing in the development of needle-less blood glucose monitoring devices to offer painless management of diabetes in patients.

For instance, GlucoTrack - a product manufactured by Integrity Applications (Israel) performs quantification using electromagnetic, ultrasonic, and thermal waves in combination. In addition, Eversense is another painless glucose monitoring subcutaneous implant offered by Senseonics. This implant is able to quantify glucose levels in interstitial fluid when placed beneath the skin. This is followed by data transmission to show the results in real time.

The latest no-code monitoring systems help in minimizing the errors that occur due to incorrect entry of strip codes. Whereas, others are incorporating noble metals such as silver, gold, and platinum which effectively reduces the electrical noise further improving accuracy.

Grand View Research has segmented the global point-of-care glucose testing market on the basis of product and region:

• Point-of-Care Glucose Testing Product Outlook {Revenue (USD Million) and Volume (Thousand Units), 2014 - 2025}
• • Accu Check Aviva Meter
  • Onetouch Verio Flex
  • i-STAT
  • Bayer CONTOUR blood glucose monitoring system
  • Freestyle Lite
  • True Metrix
  • Accu-Chek Inform II
  • StatStrip
• Point-of-Care Glucose Testing Regional Outlook {Revenue (USD Million) and Volume (Thousand Units), 2014 - 2025}
• • North America
  • • U.S.
    • Canada
  • Europe
  • • Germany
    • France
    • UK
    • Italy
    • Spain
    • Russia
  • Asia Pacific
  • • China
    • Japan
    • India
    • Korea
    • Australia
    • Singapore
  • Latin America
  • • Brazil
    • Mexico
    • MEA
    • Saudi Arabia
    • South Africa

Find more research reports on Clinical Diagnostics Industry, by Grand View Research:

• Bioinformatics in IVD Testing Market – Growing prevalence of cancer and other rare life threatening disorders such as HIV, increased research and development, cost effectiveness of genomic sequences are the growth propellers for bioinformatics in vitro diagnosis (IVD) market
• Infectious Disease Diagnostic Market – Infectious disease diagnostic market is expected to grow during the forecast period owing to the increasing prevalence of various infectious diseases such as, malaria, TB, HIV/AIDS, hepatitis, HAIs, STDs and diarrheal diseases.
• Human Papilloma Virus Testing Market – Global human papilloma virus testing market is expected to witness lucrative growth over the forecast period owing to increasing prevalence of cervical cancer. Rise in global geriatric female population is also one of the key drivers for market growth.

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com 
Web: https://www.grandviewresearch.com 
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg